In patients with completely resected EGFR‐mutated NSCLC, NOTCH1 mutation was identified as a poor prognostic factor for OS in the gefitinib group and may serve as a predictor of a poor response to gefitinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.